1,273.60
+3.45%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Zota Health Care
Its shares trade on NSE under the ticker ZOTA.NS. It has been listed since 10 May 2017. In the fiscal year to 31 March 2026, it reported revenue of ₹5.39bn and a net loss of ₹739.4m. At that date it held total assets of ₹11.31bn and shareholders' equity of ₹6.93bn.
Zota Health Care Ltd. engages in the manufacture, sale and export of pharmaceutical products. The company is headquartered in Surat, Gujarat. The company went IPO on 2017-05-10. The firm manufactures, markets, and exports pharmaceutical, ayurvedic, nutraceutical, and over the counter (OTC) products. The Company’s business model comprises three verticals, namely Domestic, Exports and Retail Pharmacy Chain (Davaindia). Its Marketing business vertical involves the direct distribution of generic drugs, OTC products, and other pharmaceutical products through the Company’s distribution network across India. The company has a portfolio of more than 3,000 products in various categories, such as generics, OTC products, allopathic, ayurvedic and others. In the Retail Pharmacy Chain business vertical, it operates a chain of pharmacy stores under the brand Davaindia. Its domestic products include AMLOTOZ AT Tab, APIXACEED 2.5 Tab, APIXACEED 5 Tab, ATRONA 10 Tab, ATRONA 20 Tab, ATRONA 40 Tab, ATRONA ASP 75 Cap, ATRONA ASP 150 Cap, ATRONA ASP 20/75 Cap, ATRONA FB Tab and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 10 May 2017
- Employees
- 338
- Website
- zotahealthcare.com ↗
Leadership
Pay as last reported
- Mr. Ketankumar ZotaNon-Executive Chairman of the Board₹53,000
- Mr. Viral MandviwalaChief Financial Officer₹660,000
- Mr. Ashvin VariyaCompliance Officer, Company Secretary₹892,000
- Mr. Moxesh ZotaExecutive Managing Director, since 2016₹3.1m
- Mr. Laxmi SharmaExecutive Director, since 2023
- Mr. Himanshu ZotaExecutive Whole-time Director, since 2015₹3.2m
- Mr. Kamlesh ZotaExecutive Whole-time Director, since 2015₹3.1m
- Mr. Viren ZotaWhole-Time Director, Head of Domestic Market, since 2008₹2.2m
- Mr. Ratilal HarkhaniPlant Manager₹1.0m
- Mr. Niralkumar ZotaHead of Domestic Market₹2.2m
- Mrs. Bhumi DoshiNon-Executive Independent Director₹71,000
- Mrs. Jayshreeben MehtaNon-Executive Independent Director₹61,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- The company employs 338 full-time staff members in Surat.
- The firm manufactures pharmaceutical, ayurvedic, and nutraceutical products.
- The portfolio includes more than 3,000 diverse product categories.
Weaknesses
- The company went public on the specific date of 10 May 2017.
- The headquarters is located in the city of Surat.
- The business relies on a distribution network across India.
Opportunities
- The company operates a retail pharmacy chain under the brand Davaindia.
- Exports are a key vertical for the pharmaceutical business model.
- Direct distribution covers generic drugs and OTC products effectively.
Threats
- The domestic product line includes AMLOTOZ AT Tab formulations.
- ATRONA 10 Tab and ATRONA 20 Tab are key items.
- ATRONA ASP 75 Cap requires careful market management.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.